Adding to the pressure is that CVS Health has retained coverage of Zepbound's arch rival Wegovy (semaglutide), sold by Novo ...

CVS Health Corp.’s drug-benefits unit negotiated a deal to make Novo Nordisk A/S’s Wegovy more widely available to its ...

This marks a shift in its approach to treating the global obesity problem. Read more at straitstimes.com. Read more at ...

CVS Health said it will significantly expand access to Novo Nordisk's blockbuster weight loss drug Wegovy for patients ...

The deal could expand access to its in-demand obesity drug at the expense of Eli Lilly, whose shares fell by double digits on ...

Prior to starting the trial, the participants also had moderate to high levels of scar tissue in the liver, known as stage 2 ...

CVS said it will expand access to blockbuster weight loss drug Wegovy for patients covered by its pharmacy benefit manager, Caremark.

CVS Health will drop the weight-loss drug Zepbound from its insured pharmacy options this summer. Employers and insurers may ...

The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its ...

A large trial showed that the weight-loss drug could reduce liver inflammation and scarring caused by the common condition ...

Novo Nordisk A/S said it would sell its popular weight-loss drug Wegovy for a steeply reduced price on several telehealth ...